Graphic Health Warnings on Cigarette Packaging Delayed Until 2023

Nov.16.2022
Graphic Health Warnings on Cigarette Packaging Delayed Until 2023
Graphic health warnings for cigarettes delayed until November 2023, per a Texas court order.

It won't be until early November 2023 that cigarette packaging and advertisements will feature graphic health warnings.


The Eastern District Court of Texas in the United States has issued an order to further delay the effective date of the Food and Drug Administration's (FDA) graphic cigarette health warning regulation from October 6, 2023, to November 6, 2023, for an additional 31 days.


According to the National Association of Tobacco Outlets (NATO), a court order issued on November 7 has extended the deadline for manufacturers and retailers to submit their preferred rotation plans for cigarette health warning labels to the FDA by 31 days.


Every tobacco manufacturer and retailer who makes their own cigarette advertisements is required to submit a plan to the FDA that outlines a schedule for rotating the use of 11 graphic cigarette health warnings in their ads. The association stated that the preferred submission deadline for the cigarette health warning rotation plan is now January 6, 2023.


According to NATO, the court is expected to make a ruling on the motion for summary judgment in the case within 31 days.


In March 2020, the FDA released a final rule about warnings that includes text and image combinations that describe some of the health risks associated with smoking. However, implementation has been repeatedly delayed after several tobacco companies requested a specific date be set.


The Eastern District Court of Texas has postponed the deadline for the final time on August 20, setting the new deadline for October 6, 2023.


These warnings must appear on the top 50% of the front and back of cigarette packaging, as well as on at least 20% of the top of cigarette advertisements. Additionally, as previously reported by Convenience Store News, these warnings must be randomly and evenly displayed and distributed on cigarette packaging, and rotated quarterly in cigarette advertisements.


There are 11 essential warnings that need to be addressed. They include:


Warning: Tobacco smoke can harm your children. Warning: Tobacco smoke can cause deadly lung diseases in non-smokers. Warning: Smoking can lead to head and neck cancer. Warning: Smoking can cause bladder cancer, leading to blood in urine. Warning: Smoking during pregnancy can hinder fetal growth. Warning: Smoking can block arteries, leading to heart disease and stroke. Warning: Smoking can cause chronic obstructive pulmonary disease, a potentially fatal lung disease. Warning: Smoking can decrease blood flow and cause erectile dysfunction. Warning: Smoking can decrease blood flow to the limbs, possibly requiring amputation. Warning: Smoking can cause type 2 diabetes, raising blood sugar. Warning: Smoking can cause cataracts, leading to blindness.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

PMI's IQOS Extends ZAMNA Electronic-Music Partnership to Spain as Vogue España Publishes Branded Content
PMI's IQOS Extends ZAMNA Electronic-Music Partnership to Spain as Vogue España Publishes Branded Content
Philip Morris International's IQOS has extended its partnership with electronic-music event brand ZAMNA to Spain, setting up a House of IQOS at ZAMNA Madrid. Vogue España and Time Out Madrid subsequently published branded content clearly labeled as collaborations with IQOS. PMI has also expanded its company-owned IQOS boutique network in Spain to seven cities this year. The company says IQOS's adjusted heated-tobacco market share in Europe reached 12.6% in the first quarter of 2026, with Spain among its stronger-performing European markets.
Sep.20
PMI Plans $71 Million Philippine Smoke-Free Expansion: BLENDS Production Established, Batangas Plant Exports to 18 Markets
PMI Plans $71 Million Philippine Smoke-Free Expansion: BLENDS Production Established, Batangas Plant Exports to 18 Markets
Philip Morris International (PMI) plans to invest approximately PHP 4.5 billion ($71 million) to expand its existing smoke-free manufacturing facility in Tanauan, Batangas, in the Philippines. The expansion is expected to be completed in 2027, with additional capacity serving domestic and export markets. The facility began manufacturing heated tobacco consumables in April 2024, including BLENDS sticks for the BONDS by IQOS platform. Philippine business media reported in October 2026 that products from the Batangas plant were being exported to 18 markets across Asia and Europe. PMI says it has invested more than $2 billion in the Philippines since 2010. The expansion adds to the country's existing manufacturing and export role within PMI's international supply chain.
company
Nov.16
Pennsylvania Vape Directory Enforcement Starts Oct. 19, Barring Retail Sales of Unlisted Products
Pennsylvania Vape Directory Enforcement Starts Oct. 19, Barring Retail Sales of Unlisted Products
Pennsylvania's Act 57 vape directory regime will reach the end of its 120-day inventory transition period on Oct. 19. Nicotine-containing e-cigarettes intended for retail sale in the state that are not listed on the Attorney General's ENDS directory will then be barred from retail sale and treated as contraband subject to seizure, forfeiture and destruction. Manufacturers face annual product certification, brand- and style-based fees and a minimum $50,000 surety bond, while retailers and wholesalers must source through licensed channels and monitor the directory.
Regulations
Oct.08
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Nicotine analogues such as 6-methylnicotine are already appearing in e-cigarettes and oral pouches, even as key human evidence remains limited. A new Nixodine-S study adds nonclinical data showing differences from nicotine in cytotoxicity and receptor activity, while independent studies point to a more complex toxicological picture. With supply-chain activity growing and FDA seeking clearer authority over nicotine analogues, the industry now faces a larger question: what evidence is needed before these substances can credibly replace nicotine?
SCIENCE
Sep.23
Iowa Sets November 16 Vape Directory Launch: Unlisted Products Face Sales Ban, Manufacturers $1,000 Daily Fines per Product
Iowa Sets November 16 Vape Directory Launch: Unlisted Products Face Sales Ban, Manufacturers $1,000 Daily Fines per Product
Iowa plans to publish its first vapor products directory on November 16, 2026, after which products not listed will be prohibited from sale or offer for sale in the state. The Department of Revenue expects to begin penalty enforcement on December 17, following an initial 21-business-day period focused on compliance education. Under House File 2677, retailers, distributors and wholesalers selling unlisted products face civil penalties of $300 per product per day, while manufacturers face $1,000 per product per day. Eligibility extends to FDA-authorized products and certain products meeting historical marketing and pending PMTA requirements. The directory program resumed after a federal appeals court vacated a preliminary injunction in July 2026.
Regulations
Nov.05
Product | PMI Launches ZYN Melts in UK, Extending ZYN Beyond Nicotine Pouches Into Dissolvable Tablets
Product | PMI Launches ZYN Melts in UK, Extending ZYN Beyond Nicotine Pouches Into Dissolvable Tablets
Philip Morris International (PMI) has launched ZYN Melts in the UK, introducing a fully dissolvable oral nicotine tablet format alongside the brand's existing nicotine pouches. The range includes Cool Mint and Peppermint, each offered at 1mg and 2mg of nicotine per tablet, creating four SKUs. Each can contains 20 tablets and is priced at £6.50 in the UK. Unlike ZYN nicotine pouches, Melts are placed between the upper lip and gum and dissolve completely during use.
News
Sep.29 by 2Firsts Perspectives